Palvella Therapeutics annual operating margin
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Palvella Therapeutics Operating Margin Growth & History (PVLA)
Palvella Therapeutics's operating margin was −30.66% for fiscal 2023.
View full Palvella Therapeutics company overviewPalvella Therapeutics annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2023 | 2023-12-31 | −30.66% | +140.03 pp |
| 2022 | 2022-12-31 | −170.69% | +14.81 pp |
| 2021 | 2021-12-31 | −185.51% | −43.64 pp |
| 2020 | 2020-12-31 | −141.86% | −79.64 pp |
| 2019 | 2019-12-31 | −62.22% | +50.93 pp |
| 2018 | 2018-12-31 | −113.15% | −55.41 pp |
| 2017 | 2017-12-31 | −57.74% | +332.57 pp |
| 2016 | 2016-12-31 | −390.31% | +76.31 pp |
| 2015 | 2015-12-31 | −466.62% | −332.45 pp |
| 2014 · Dec 31 | 2014-12-31 | −134.17% | −138.63 pp |
| 2013 | 2013-12-31 | 4.46% | — |
Palvella Therapeutics quarterly operating margin
Q1.14
Q4.14
Q1.15
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q1 2024 | 2024-03-31 | −29,316.67% | −28544.98 pp |
| Q4 2023 | 2023-12-31 | 1,279.73% | +1481.50 pp |
| Q3 2023 | 2023-09-30 | −75.84% | +162.19 pp |
| Q2 2023 | 2023-06-30 | 10.27% | +365.81 pp |
| Q1 2023 | 2023-03-31 | −771.69% | −704.99 pp |
| Q4 2022 | 2022-12-31 | −201.77% | −59.86 pp |
| Q3 2022 | 2022-09-30 | −238.03% | +445.12 pp |
| Q2 2022 | 2022-06-30 | −355.54% | +304.35 pp |
| Q1 2022 | 2022-03-31 | −66.70% | −32.67 pp |
| Q4 2021 | 2021-12-31 | −141.90% | +675.68 pp |
| Q3 2021 | 2021-09-30 | −683.15% | −178.92 pp |
| Q2 2021 | 2021-06-30 | −659.88% | −617.29 pp |
| Q1 2021 | 2021-03-31 | −34.03% | +9.37 pp |
| Q4 2020 | 2020-12-31 | −817.59% | −809.62 pp |
| Q3 2020 | 2020-09-30 | −504.23% | −484.13 pp |
| Q2 2020 | 2020-06-30 | −42.59% | +205.28 pp |
| Q1 2020 | 2020-03-31 | −43.40% | +98.40 pp |
| Q4 2019 | 2019-12-31 | −7.97% | +260.73 pp |
| Q3 2019 | 2019-09-30 | −20.10% | +79.02 pp |
| Q2 2019 | 2019-06-30 | −247.87% | −227.89 pp |
| Q1 2019 | 2019-03-31 | −141.80% | +94.44 pp |
| Q4 2018 | 2018-12-31 | −268.71% | −304.44 pp |
| Q3 2018 | 2018-09-30 | −99.12% | +32.89 pp |
| Q2 2018 | 2018-06-30 | −19.98% | +405.87 pp |
| Q1 2018 | 2018-03-31 | −236.24% | +359.89 pp |
| Q4 2017 | 2017-12-31 | 35.74% | +270.65 pp |
| Q3 2017 | 2017-09-30 | −132.01% | +654.99 pp |
| Q2 2017 | 2017-06-30 | −425.85% | +114.34 pp |
| Q1 2017 | 2017-03-31 | −596.13% | −244.73 pp |
| Q4 2016 | 2016-12-31 | −234.91% | −115.01 pp |
| Q3 2016 | 2016-09-30 | −786.99% | +148.80 pp |
| Q2 2016 | 2016-06-30 | −540.19% | +1665.47 pp |
| Q1 2016 | 2016-03-31 | −351.40% | +1349.42 pp |
| Q4 2015 | 2015-12-31 | −119.91% | −61.41 pp |
| Q3 2015 | 2015-09-30 | −935.79% | +8897.01 pp |
| Q2 2015 | 2015-06-30 | −2,205.66% | −1808.95 pp |
| Q1 2015 · Mar 31 | 2015-03-31 | −1,700.82% | −1651.92 pp |
| Q4 2014 | 2014-12-31 | −58.50% | — |
| Q1 2015 · Sep 30 | 2014-09-30 | −9,832.80% | — |
| Q4 2014 | 2014-06-30 | −396.71% | — |
| Q1 2014 · Mar 31 | 2014-03-31 | −48.89% | — |
Palvella Therapeutics operating margin trends
Over the last five reported fiscal years, Palvella Therapeutics's operating margin increased from −113.15% to −30.66%, a change of +82.49 percentage points. The latest reported quarter, Q1 2024, shows −29,316.67%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Palvella Therapeutics filings at SEC.gov ↗